Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection

References

• Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger B-M, Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707–16. doi:10.1038/ni.2939.
   PubMed Web of Science ®Google Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119:5640–49. doi:10.1182/blood-2012-01-380121.
   PubMed Web of Science ®Google Scholar
• Rosenfeld SI, Looney RJ, Leddy JP, Phipps DC, Abraham GN, Anderson CL. Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes. J Clin Invest. 1985;76:2317–22. doi:10.1172/JCI112242.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985;162:2089–106. doi:10.1084/jem.162.6.2089.
   PubMed Web of Science ®Google Scholar
• Bertagnolli LN, White JA, Simonetti FR, Beg SA, Lai J, Tomescu C, Murray AJ, Antar AAR, Zhang H, Margolick JB, et al. The role of CD32 during HIV-1 infection. Nature. 2018;561:E17–E19. doi:10.1038/s41586-018-0494-3.
   PubMed Web of Science ®Google Scholar
• Badia R, Ballana E, Castellví M, García-Vidal E, Pujantell M, Clotet B, Prado JG, Puig J, Martínez MA, Riveira-Muñoz E, et al. CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir. Nat Commun. 2018;9:2739. doi:10.1038/s41467-018-05157-w.
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–25. doi:10.1182/blood-2008-09-179754.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108:12669–74. doi:10.1073/pnas.1108455108.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A. 2013;110:9868–72. doi:10.1073/pnas.1307864110.
   PubMed Web of Science ®Google Scholar
• Patel KR, Roberts JT, Barb AW. Multiple variables at the leukocyte cell surface impact Fc gamma receptor-dependent mechanisms. Front Immunol. 2019;10:223. doi:10.3389/fimmu.2019.00223.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat Immunol. 2018;19:1169–78. doi:10.1038/s41590-018-0233-9.
   PubMed Web of Science ®Google Scholar
• He W, Tan GS, Mullarkey CE, Lee AJ, Lam MMW, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A. 2016;113(42):11931–36. doi:10.1073/pnas.1609316113.
   PubMed Web of Science ®Google Scholar
• Bakalar MH, Joffe AM, Schmid EM, Son S, Podolski M, Fletcher DA. Size-dependent segregation controls macrophage phagocytosis of antibody-opsonized targets. Cell. 2018;174(1):131–142 e113. doi:10.1016/j.cell.2018.05.059.
   PubMed Web of Science ®Google Scholar
• Hanson QM, Barb AW. A perspective on the structure and receptor binding properties of immunoglobulin G Fc. Biochemistry. 2015;54:2931–42. doi:10.1021/acs.biochem.5b00299.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. 1999;10:753–60. doi:10.1016/s1074-7613(00)80074-6.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by antibodies: recent progress. Annu Rev Immunol. 2017;35:285–311. doi:10.1146/annurev-immunol-051116-052433.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475:110–13. doi:10.1038/nature10134.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373–76. doi:10.1126/science.1154315.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. 2008;105:19571–78. doi:10.1073/pnas.0810163105.
   PubMed Web of Science ®Google Scholar
• Wang TT, Maamary J, Tan G, Bournazos S, Davis C, Krammer F, Schlesinger S, Palese P, Ahmed R, Ravetch J, et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell. 2015;162:160–69. doi:10.1016/j.cell.2015.06.026.
   PubMed Web of Science ®Google Scholar
• Temming AR, Dekkers G, van de Bovenkamp FS, Plomp HR, Bentlage AEH, Szittner Z, Derksen NIL, Wuhrer M, Rispens T, Vidarsson G, et al. Author correction: human DC-SIGN and CD23 do not interact with human IgG. Sci Rep. 2020;10:12560. doi:10.1038/s41598-020-68760-2.
   PubMed Web of Science ®Google Scholar
• Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol. 2013;425:1253–58. doi:10.1016/j.jmb.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Tjon AS, Van Gent R, Geijtenbeek TB, Kwekkeboom J. Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: more than meets the eye. Front Immunol. 2015;6:197. doi:10.3389/fimmu.2015.00197.
   PubMed Web of Science ®Google Scholar
• Braakman E, van de Winkel JG, van Krimpen BA, Jansze M, Bolhuis RL. CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell Immunol. 1992;143:97–107. doi:10.1016/0008-8749(92)90008-d.
   PubMed Web of Science ®Google Scholar
• Richard J, Prévost J, Baxter AE, von Bredow B, Ding S, Medjahed H, Delgado GG, Brassard N, Stürzel CM, Kirchhoff F, et al. Uninfected bystander cells impact the measurement of HIV-specific antibody-dependent cellular cytotoxicity responses. mBio. 2018;9. doi:10.1128/mBio.00358-18.
   Web of Science ®Google Scholar
• Prevost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, Ochsenbauer C, Finzi A. Incomplete downregulation of CD4 expression affects HIV-1 Env conformation and antibody-dependent cellular cytotoxicity responses. J Virol. 2018:92. doi:10.1128/JVI.00484-18.
   Web of Science ®Google Scholar
• Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41–51. doi:10.1016/j.immuni.2005.05.010.
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006;308:53–67. doi:10.1016/j.jim.2005.09.018.
   PubMed Web of Science ®Google Scholar
• Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294:15–22. doi:10.1016/j.jim.2004.08.008.
   PubMed Web of Science ®Google Scholar
• Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol. 2009;182:1202–10. doi:10.4049/jimmunol.182.2.1202.
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Moldt B, Wyatt RT, Dugast A-S, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366(1–2):8–19. doi:10.1016/j.jim.2010.12.016.
   PubMed Web of Science ®Google Scholar
• Karsten CB, Mehta N, Shin SA, Diefenbach TJ, Slein MD, Karpinski W, Irvine EB, Broge T, Suscovich TJ, Alter G, et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J Immunol Methods. 2019;471:46–56. doi:10.1016/j.jim.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Butler AL, Fallon JK, Alter G. A sample-sparing multiplexed ADCP assay. Front Immunol. 2019;10:1851. doi:10.3389/fimmu.2019.01851.
   PubMed Web of Science ®Google Scholar
• Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7:2517–27. doi:10.1158/1535-7163.MCT-08-0201.
   PubMed Web of Science ®Google Scholar
• Bakema JE, van Egmond M. The human immunoglobulin A Fc receptor FcalphaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 2011;4:612–24. doi:10.1038/mi.2011.36.
   PubMed Web of Science ®Google Scholar
• Huang ZY, Hunter S, Chien P, Kim M-K, Han-Kim T-H, Indik ZK, Schreiber AD. Interaction of two phagocytic host defense systems: fcgamma receptors and complement receptor 3. J Biol Chem. 2011;286:160–68. doi:10.1074/jbc.M110.163030.
   PubMed Web of Science ®Google Scholar
• Fischinger S, Fallon JK, Michell AR, Broge T, Suscovich TJ, Streeck H, Alter G. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation. J Immunol Methods. 2019;473:112630. doi:10.1016/j.jim.2019.07.002.
   PubMed Web of Science ®Google Scholar
• Duensing TD, Watson SR. Complement-dependent cytotoxicity assay. Cold Spring Harb Protoc. 2018:2018. doi:10.1101/pdb.prot093799.
   Google Scholar
• Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, Abdool Karim S, Moore PL, Ackerman ME, Alter G, et al. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018;14(4):e1006987. doi:10.1371/journal.ppat.1006987.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Babes L, Zhao XW, van Houdt M, Treffers LW, van Rees DJ, Franke K, Schornagel K, Verkuijlen P, Janssen H, et al. Neutrophils kill antibody-opsonized cancer cells by trogoptosis. Cell Rep. 2018;23:3946–3959 e3946. doi:10.1016/j.celrep.2018.05.082.
   PubMed Web of Science ®Google Scholar
• Richardson SI, Crowther C, Mkhize NN, Morris L. Measuring the ability of HIV-specific antibodies to mediate trogocytosis. J Immunol Methods. 2018;463:71–83. doi:10.1016/j.jim.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, Kelly HG, Haycroft ER, Tan H-X, Juno JA, et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Rep Med. 2021;2(6):100296. doi:10.1016/j.xcrm.2021.100296.
   PubMedGoogle Scholar
• Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, Moreau J-F, Déchanet-Merville J. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood. 2012;119:1418–27. doi:10.1182/blood-2011-06-363655.
   PubMed Web of Science ®Google Scholar
• Farrington LA, Callaway PC, Vance HM, Baskevitch K, Lutz E, Warrier L, McIntyre TI, Budker R, Jagannathan P, Nankya F, et al. Opsonized antigen activates Vdelta2+ T cells via CD16/FCgammaRIIIa in individuals with chronic malaria exposure. PLoS Pathog. 2020;16:e1008997. doi:10.1371/journal.ppat.1008997.
   PubMed Web of Science ®Google Scholar
• Palankar R, Kohler TP, Krauel K, Wesche J, Hammerschmidt S, Greinacher A. Platelets kill bacteria by bridging innate and adaptive immunity via platelet factor 4 and Fcγ RIIA. J Thromb Haemost. 2018;16:1187–97. doi:10.1111/jth.13955.
   PubMed Web of Science ®Google Scholar
• Riaz AH, Tasma BE, Woodman ME, Wooten RM, Worth RG. Human platelets efficiently kill IgG-opsonized E. coli. FEMS Immunol Med Microbiol. 2012;65:78–83. doi:10.1111/j.1574-695X.2012.00945.x.
   PubMedGoogle Scholar
• Apostolidis SA, Sarkar A, Giannini HM, Goel RR, Mathew D, Suzuki A, Baxter AE, Greenplate AR, Alanio C, Abdel-Hakeem M, et al. Signaling through FcgammaRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19. bioRxiv. 2021. doi:10.1101/2021.05.01.442279.
   Google Scholar
• Lofano G, Gorman MJ, Yousif AS, Yu W-H, Fox JM, Dugast A-S, Ackerman ME, Suscovich TJ, Weiner J, Barouch D, et al. Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. Sci Immunol. 2018;3. doi:10.1126/sciimmunol.aat7796.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. 2015;161:1035–45. doi:10.1016/j.cell.2015.04.016.
   PubMed Web of Science ®Google Scholar
• Chung AW, Kumar M, Arnold K, Yu W, Schoen M, Dunphy L, Suscovich T, Frahm N, Linde C, Mahan A, et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell. 2015;163(4):988–98. doi:10.1016/j.cell.2015.10.027.
   PubMed Web of Science ®Google Scholar
• Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, et al. Systematic analysis of monoclonal antibodies against ebola virus GP defines features that contribute to protection. Cell. 2018;174(4):938–952 e913. doi:10.1016/j.cell.2018.07.033.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Yu W-H, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, et al. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host Microbe. 2018;24(2):221–233 e225. doi:10.1016/j.chom.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, McCulloch DJ, Newman KL, Wolf C, Yu J, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;53(3):524–532 e524. doi:10.1016/j.immuni.2020.07.020.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves first treatment for ebola virus. Press Release; 2020.
   Google Scholar
• FDA. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. Press Release; 2020.
   Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vasquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Smith SA, Crowe JE Jr. Use of human hybridoma technology to isolate human monoclonal antibodies. Microbiol Spectr. 2015;3:AID-0027-2014. doi:10.1128/microbiolspec.AID-0027-2014.
   Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr. 2014:2. doi:10.1128/microbiolspec.AID-0018-2014.
   PubMedGoogle Scholar
• Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016;351(6277):1078–83. doi:10.1126/science.aad5788.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol. 2018;3:670–77. doi:10.1038/s41564-018-0157-z.
   PubMed Web of Science ®Google Scholar
• Duehr J, McMahon M, Williamson B, Amanat F, Durbin A, Hawman DW, Noack D, Uhl S, Tan GS, Feldmann H, et al. Neutralizing monoclonal antibodies against the Gn and the Gc of the Andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model. mBio. 2020;11(2). doi:10.1128/mBio.00028-20.
   PubMed Web of Science ®Google Scholar
• Garrido JL, Prescott J, Calvo M, Bravo F, Alvarez R, Salas A, Riquelme R, Rioseco ML, Williamson BN, Haddock E, et al. Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. Sci Transl Med. 2018;10(468):eaat6420. doi:10.1126/scitranslmed.aat6420.
   PubMed Web of Science ®Google Scholar
• Chapman NS, Zhao H, Kose N, Westover JB, Kalveram B, Bombardi R, Rodriguez J, Sutton R, Genualdi J, LaBeaud AD, et al. Potent neutralization of rift valley fever virus by human monoclonal antibodies through fusion inhibition. Proc Natl Acad Sci U S A. 2021;118. doi:10.1073/pnas.2025642118.
   Web of Science ®Google Scholar
• Allen ER, Krumm SA, Raghwani J, Halldorsson S, Elliott A, Graham VA, Koudriakova E, Harlos K, Wright D, Warimwe GM, et al. A protective monoclonal antibody targets a site of vulnerability on the surface of rift valley fever virus. Cell Rep. 2018;25(13):3750–3758 e3754. doi:10.1016/j.celrep.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013;9:e1003312. doi:10.1371/journal.ppat.1003312.
   PubMed Web of Science ®Google Scholar
• Kuehnert PA, Stefan CP, Badger CV, Ricks KM. Crimean-Congo hemorrhagic fever virus (CCHFV): a Silent but widespread threat. Curr Trop Med Rep. 2021:1–7. doi:10.1007/s40475-021-00235-4.
   Google Scholar
• Kruger DH, Figueiredo LT, Song JW, Klempa B. Hantaviruses–globally emerging pathogens. J Clin Virol. 2015;64:128–36. doi:10.1016/j.jcv.2014.08.033.
   PubMed Web of Science ®Google Scholar
• Swei A, Couper LI, Coffey LL, Kapan D, Bennett S. Patterns, drivers, and challenges of vector-borne disease emergence. Vector Borne Zoonotic Dis. 2020;20:159–70. doi:10.1089/vbz.2018.2432.
   PubMed Web of Science ®Google Scholar
• Wine Y, Horton AP, Ippolito GC, Georgiou G. Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire. Curr Opin Immunol. 2015;35:89–97. doi:10.1016/j.coi.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA, Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity. Science. 2017;355:395–98. doi:10.1126/science.aai8128.
   PubMed Web of Science ®Google Scholar
• Gomez RS, Ramirez BA, Céspedes PF, Cautivo KM, Riquelme SA, Prado CE, González PA, Kalergis AM. Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells. Immunology. 2016;147:55–72. doi:10.1111/imm.12541.
   PubMed Web of Science ®Google Scholar
• Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE, et al. Antibody-dependent enhancement of ebola virus infection by human antibodies isolated from survivors. Cell Rep. 2018;24(7):1802–1815 e1805. doi:10.1016/j.celrep.2018.07.035.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, Peters CJ, Parren PW, Burton DR. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73:6024–30. doi:10.1128/JVI.73.7.6024-6030.1999.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664–66. doi:10.1126/science.287.5458.1664.
   PubMed Web of Science ®Google Scholar
• Olinger GG Jr., Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109:18030–35. doi:10.1073/pnas.1213709109.
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53. doi:10.1038/nature13777.
   PubMed Web of Science ®Google Scholar
• Misasi J, Gilman MSA, Kanekiyo M, Gui M, Cagigi A, Mulangu S, Corti D, Ledgerwood JE, Lanzavecchia A, Cunningham J, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016;351(6279):1343–46. doi:10.1126/science.aad6117.
   PubMed Web of Science ®Google Scholar
• Wec AZ, Bornholdt ZA, He S, Herbert AS, Goodwin E, Wirchnianski AS, Gunn BM, Zhang Z, Zhu W, Liu G, et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe. 2019;25:39–48 e35. doi:10.1016/j.chom.2018.12.004.
   PubMed Web of Science ®Google Scholar
• Flyak AI, Shen X, Murin C, Turner H, David J, Fusco M, Lampley R, Kose N, Ilinykh P, Kuzmina N, et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell. 2016. doi:10.1016/j.cell.2015.12.022.
   PubMed Web of Science ®Google Scholar
• Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, et al. Development of clinical-stage human monoclonal antibodies that treat advanced ebola virus disease in nonhuman primates. J Infect Dis. 2018;218(suppl_5):S612–S626. doi:10.1093/infdis/jiy285.
   PubMed Web of Science ®Google Scholar
• Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang C-I, Lei L, Fels JM, et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell. 2017;169(5):891–904 e815. doi:10.1016/j.cell.2017.04.038.
   PubMed Web of Science ®Google Scholar
• Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, et al. Pan-ebolavirus and pan-filovirus mouse monoclonal antibodies: protection against ebola and Sudan viruses. J Virol. 2016;90(1):266–78. doi:10.1128/JVI.02171-15.
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–303. doi:10.1056/NEJMoa1910993.
   PubMed Web of Science ®Google Scholar
• PREVAIL II Writing Group, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448–56. doi:10.1056/NEJMoa1604330.
   PubMed Web of Science ®Google Scholar
• Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, De La Vega M-A, Zhu W, et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell. 2017;169:878–890 e815. doi:10.1016/j.cell.2017.04.037.
   PubMed Web of Science ®Google Scholar
• Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, et al. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep. 2016;15(7):1514–26. doi:10.1016/j.celrep.2016.04.026.
   PubMed Web of Science ®Google Scholar
• Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein. Immunity. 2018;49(2):363–374 e310. doi:10.1016/j.immuni.2018.06.018.
   PubMed Web of Science ®Google Scholar
• Ilinykh PA, Huang K, Santos RI, Gilchuk P, Gunn BM, Karim MM, Liang J, Fouch ME, Davidson E, Parekh DV, et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-Effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe. 2020;27:976–991 e911. doi:10.1016/j.chom.2020.03.025.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011;108:20690–94. doi:10.1073/pnas.1108360108.
   PubMed Web of Science ®Google Scholar
• Bornholdt ZA, Herbert AS, Mire CE, He S, Cross RW, Wec AZ, Abelson DM, Geisbert JB, James RM, Rahim MN, et al. A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe. 2019;25:49–58 e45. doi:10.1016/j.chom.2018.12.005.
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122:3482–91. doi:10.1182/blood-2013-05-504043.
   PubMed Web of Science ®Google Scholar
• Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56(7):1227–37. doi:10.1093/rheumatology/kex067.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016;126:605–10. doi:10.1172/JCI84428.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Klein F, Pietzsch J, Seaman M, Nussenzweig M, Ravetch J. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158:1243–53. doi:10.1016/j.cell.2014.08.023.
   PubMed Web of Science ®Google Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012;86:6189–96. doi:10.1128/JVI.00491-12.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, Buffone C, Kathale N, Providenza S, Xie MM, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22(1):67–73. doi:10.1038/s41590-020-00828-7.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Vo HTM, Duong V, Auerswald H, Ly S, Sakuntabhai A, Dussart P, Cantaert T, Ravetch JV. Antibody fucosylation predicts disease severity in secondary dengue infection. Science. 2021;372(6546):1102–05. doi:10.1126/science.abc7303.
   PubMed Web of Science ®Google Scholar
• Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, Chen H-J, Linty F, Visser R, Brinkhaus M, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science. 2021;371(6532):eabc8378. doi:10.1126/science.abc8378.
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, Lanigan CMS, Landucci G, Forthal DN, Parren PWHI, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449(7158):101–04. doi:10.1038/nature06106.
   PubMed Web of Science ®Google Scholar
• Halper-Stromberg A, Lu C-L, Klein F, Horwitz J, Bournazos S, Nogueira L, Eisenreich T, Liu C, Gazumyan A, Schaefer U, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014;158(5):989–99. doi:10.1016/j.cell.2014.07.043.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med. 2014;20:143–51. doi:10.1038/nm.3443.
   PubMed Web of Science ®Google Scholar
• Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371(6531):823–29. doi:10.1126/science.abf4830.
   PubMed Web of Science ®Google Scholar
• Schafer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, et al. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 2021;218(3). doi:10.1084/jem.20201993.
   Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. bioRxiv. 2020. doi:10.1101/2020.12.28.424554.
   Google Scholar
• Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–95. doi:10.1038/s41586-020-2349-y.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–14. doi:10.1126/science.abd0827.
   PubMed Web of Science ®Google Scholar
• Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcgammaR interaction on monocytes. Sci Immunol. 2019;4:eaav5062. doi:10.1126/sciimmunol.aav5062.
   PubMed Web of Science ®Google Scholar
• Earnest JT, Basore K, Roy V, Bailey AL, Wang D, Alter G, Fremont DH, Diamond MS. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. J Exp Med. 2019;216(10):2282–301. doi:10.1084/jem.20190736.
   PubMed Web of Science ®Google Scholar
• Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Lodrigue K, Liao LE, Perelson AS, Huang Y, et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. Proc Natl Acad Sci U S A. 2020;117:18002–09. doi:10.1073/pnas.2008190117.
   PubMed Web of Science ®Google Scholar
• Parsons MS, Lee WS, Kristensen AB, Amarasena T, Khoury G, Wheatley AK, Reynaldi A, Wines BD, Hogarth PM, Davenport MP, et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J Clin Invest. 2019;129(1):182–91. doi:10.1172/JCI122466.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804–1820.e16. doi:10.1016/j.cell.2021.02.026.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Lu R, Slein MD, Ilinykh PA, Huang K, Atyeo C, Schendel SL, Kim J, Cain C, Roy V, et al. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity. 2021;54(4):815–828 e815. doi:10.1016/j.immuni.2021.03.009.
   PubMed Web of Science ®Google Scholar
• Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. Differential requirements for FcgammaR engagement by protective antibodies against Ebola virus. Proc Natl Acad Sci U S A. 2019;116:20054–62. doi:10.1073/pnas.1911842116.
   PubMed Web of Science ®Google Scholar
• Leon PE, He W, Mullarkey CE, Bailey MJ, Miller MS, Krammer F, Palese P, Tan GS. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc Natl Acad Sci U S A. 2016;113(40):E5944–E5951. doi:10.1073/pnas.1613225113.
   PubMed Web of Science ®Google Scholar
• Tolbert WD, Sherburn R, Gohain N, Ding S, Flinko R, Orlandi C, Ray K, Finzi A, Lewis GK, Pazgier M, et al. Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site. BMC Biol. 2020;18(1):91. doi:10.1186/s12915-020-00819-y.
   PubMed Web of Science ®Google Scholar
• Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, Lovo E, Wu X, Robinson JE, Seaman MS, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A. 2013;110(1):E69–78. doi:10.1073/pnas.1217609110.
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Bovendo HF, et al. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med. 2016;8(329):329ra333. doi:10.1126/scitranslmed.aad9875.
   Web of Science ®Google Scholar
• Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P, et al. Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner. mBio. 2016;7(5). doi:10.1128/mBio.01624-16.
   PubMed Web of Science ®Google Scholar
• Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, et al. Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proc Natl Acad Sci U S A. 2021;118. doi:10.1073/pnas.2018102118.
   PubMed Web of Science ®Google Scholar
• Temming AR, De Taeye SW, de Graaf EL, de Neef LA, Dekkers G, Bruggeman CW, Koers J, Ligthart P, Nagelkerke SQ, Zimring JC, et al. Functional attributes of antibodies, effector cells, and target cells affecting NK cell-mediated antibody-dependent cellular cytotoxicity. J Immunol. 2019;203:3126–35. doi:10.4049/jimmunol.1900985.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–58. doi:10.1182/blood.v99.3.754.
   PubMed Web of Science ®Google Scholar
• Breunis WB, van Mirre E, Bruin M, Geissler J, De Boer M, Peters M, Roos D, De Haas M, Koene HR, Kuijpers TW, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood. 2008;111(3):1029–38. doi:10.1182/blood-2007-03-079913.
   PubMed Web of Science ®Google Scholar
• Ernst LK, Metes D, Herberman RB, Morel PA. Allelic polymorphisms in the FcgammaRIIC gene can influence its function on normal human natural killer cells. J Mol Med (Berl). 2002;80:248–57. doi:10.1007/s00109-001-0294-2.
   PubMed Web of Science ®Google Scholar
• Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo C-W, Zolla-Pazner S, Montefiori D, Liao H-X, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest. 2014;124(9):3879–90. doi:10.1172/JCI75539.
   PubMed Web of Science ®Google Scholar
• Li SS, Gilbert PB, Carpp LN, Pyo C-W, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, et al. Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 Risk in the HVTN 505 HIV vaccine trial. J Virol. 2019;93(21). doi:10.1128/JVI.02041-18.
   Web of Science ®Google Scholar
• Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood. 1991;78:885–89. doi:10.1182/blood.V78.4.885.885.
   PubMed Web of Science ®Google Scholar
• Wang Y, Jonsson F. Expression, role, and regulation of neutrophil Fcgamma receptors. Front Immunol. 2019;10:1958. doi:10.3389/fimmu.2019.01958.
   PubMed Web of Science ®Google Scholar
• Mendoza-Coronel E, Ortega E. Macrophage polarization modulates FcgammaR- and CD13-mediated phagocytosis and reactive oxygen species production, independently of receptor membrane expression. Front Immunol. 2017;8:303. doi:10.3389/fimmu.2017.00303.
   PubMed Web of Science ®Google Scholar
• Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15:335–49. doi:10.1038/nri3843.
   PubMed Web of Science ®Google Scholar
• Rice P, Martin E, He J-R, Frank M, DeTolla L, Hester L, O’Neill T, Manka C, Benjamin I, Nagarsekar A, et al. Febrile-range hyperthermia augments neutrophil accumulation and enhances lung injury in experimental gram-negative bacterial pneumonia. J Immunol. 2005;174:3676–85. doi:10.4049/jimmunol.174.6.3676.
   PubMed Web of Science ®Google Scholar
• Lin C, Zhang Y, Zhang K, Zheng Y, Lu L, Chang H, Yang H, Yang Y, Wan Y, Wang S, et al. Fever promotes T lymphocyte trafficking via a thermal sensory pathway involving heat shock protein 90 and alpha4 integrins. Immunity. 2019;50:137–151 e136. doi:10.1016/j.immuni.2018.11.013.
   PubMed Web of Science ®Google Scholar
• Hasday JD, Garrison A, Singh IS, Standiford T, Ellis GS, Rao S, He J-R, Rice P, Frank M, Goldblum SE, et al. Febrile-range hyperthermia augments pulmonary neutrophil recruitment and amplifies pulmonary oxygen toxicity. Am J Pathol. 2003;162(6):2005–17. doi:10.1016/S0002-9440(10)64333-7.
   PubMed Web of Science ®Google Scholar
• Zanker KS, Lange J. Whole body hyperthermia and natural killer cell activity. Lancet. 1982;1:1079–80. doi:10.1016/s0140-6736(82)92142-0.
   PubMed Web of Science ®Google Scholar
• Hatzfeld-Charbonnier AS, Lasek A, Castera L, Gosset P, Velu T, Formstecher P, Mortier L, Marchetti P. Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines. J Leukoc Biol. 2007;81(5):1179–87. doi:10.1189/jlb.0506347.
   PubMed Web of Science ®Google Scholar
• Dowd KA, Pierson TC. The many faces of a dynamic virion: implications of viral breathing on flavivirus biology and immunogenicity. Annu Rev Virol. 2018;5:185–207. doi:10.1146/annurev-virology-092917-043300.
   PubMed Web of Science ®Google Scholar
• McElroy AK, Akondy RS, Mcllwain DR, Chen H, Bjornson-Hooper Z, Mukherjee N, Mehta AK, Nolan G, Nichol ST, Spiropoulou CF, et al. Immunologic timeline of Ebola virus disease and recovery in humans. JCI Insight. 2020;5(10). doi:10.1172/jci.insight.137260.
   PubMed Web of Science ®Google Scholar
• Ludtke A, Ruibal P, Becker-Ziaja B, Rottstegge M, Wozniak DM, Cabeza-Cabrerizo M, Thorenz A, Weller R, Kerber R, Idoyaga J, et al. Ebola virus disease is characterized by poor activation and reduced levels of circulating CD16+monocytes. J Infect Dis. 2016;214(suppl 3):S275–S280. doi:10.1093/infdis/jiw260.
   PubMedGoogle Scholar
• Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe‐Tamfum J. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International scientific and technical committee. J Infect Dis. 1999;179(Suppl 1):S18–23. doi:10.1086/514298.
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109:5034–39. doi:10.1073/pnas.1200409109.
   PubMed Web of Science ®Google Scholar
• Mire CE, Geisbert JB, Agans KN, Thi EP, Lee ACH, Fenton KA, Geisbert TW. Passive immunotherapy: assessment of convalescent serum against ebola virus makona infection in nonhuman primates. J Infect Dis. 2016;214:S367–S374. doi:10.1093/infdis/jiw333.
   PubMed Web of Science ®Google Scholar
• Van Griensven J, Edwards T, De Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, et al. Evaluation of convalescent plasma for ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi:10.1056/NEJMoa1511812.
   PubMed Web of Science ®Google Scholar
• Van Griensven J, Edwards T, Baize S, Ebola-Tx C. Efficacy of convalescent plasma in relation to dose of ebola virus antibodies. N Engl J Med. 2016;375:2307–09. doi:10.1056/NEJMc1609116.
   PubMed Web of Science ®Google Scholar
• Brown JF, Dye JM, Tozay S, Jeh-Mulbah G, Wohl DA, Fischer WA, Cunningham CK, Rowe K, Zacharias P, van Hasselt J, et al. Anti-ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with ebola virus disease. J Infect Dis. 2018;218:555–62. doi:10.1093/infdis/jiy199.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Roy V, Karim MM, Hartnett JN, Suscovich TJ, Goba A, Momoh M, Sandi JD, Kanneh L, Andersen KG, et al. Survivors of ebola virus disease develop polyfunctional antibody responses. J Infect Dis. 2020;221(1):156–61. doi:10.1093/infdis/jiz364.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, Wiggins CC, Bruno KA, Klompas AM, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015–27. doi:10.1056/NEJMoa2031893.
   PubMed Web of Science ®Google Scholar
• Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, Littlefield K, Wieland-Alter W, Connor RI, Wright PF, et al. Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma. mBio. 2021;12(2). doi:10.1128/mBio.00765-21.
   PubMed Web of Science ®Google Scholar
• Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao J-A, Matsushita H, Sathiyaseelan J, Wu H, Mellquist J, Hammitt M, Koster J, et al. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol. 2009;27(2):173–81. doi:10.1038/nbt.1521.
   PubMed Web of Science ®Google Scholar
• Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao J-A, Matsushita H, Liu Y, Postnikova EN, Ork BL, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016;8(326):326ra321. doi:10.1126/scitranslmed.aaf1061.
   Web of Science ®Google Scholar
• Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao J-A, Matsushita H, et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med. 2014;6(264):264ra162. doi:10.1126/scitranslmed.3010082.
   PubMed Web of Science ®Google Scholar
• Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, et al. Fully human immunoglobulin G from transchromosomic bovines treats nonhuman primates infected with ebola virus makona isolate. J Infect Dis. 2018;218(suppl_5):S636–S648. doi:10.1093/infdis/jiy377.
   PubMedGoogle Scholar
• Jin C, Hill J, Gunn BM, Yu W-H, Dahora LC, Jones E, Johnson M, Gibani MM, Spreng RL, Alam SM, et al. Vi-specific serological correlates of protection for typhoid fever. J Exp Med. 2021;218(2). doi:10.1084/jem.20201116.
   Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–86. doi:10.1056/NEJMoa1113425.
   PubMed Web of Science ®Google Scholar
• Alter G, Yu W-H, Chandrashekar A, Borducchi EN, Ghneim K, Sharma A, Nedellec R, McKenney KR, Linde C, Broge T, et al. Passive transfer of vaccine-elicited antibodies protects against SIV in rhesus macaques. Cell. 2020;183(1):185–196 e114. doi:10.1016/j.cell.2020.08.033.
   PubMed Web of Science ®Google Scholar
• Om K, Paquin-Proulx D, Montero M, Peachman K, Shen X, Wieczorek L, Beck Z, Weiner JA, Kim D, Li Y, et al. Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathog. 2020;16(9):e1008764. doi:10.1371/journal.ppat.1008764.
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast A-S, Heizen EL, Ercan A, Choi I, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123(5):2183–92. doi:10.1172/JCI65708.
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, Suscovich TJ, Alter G. Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog. 2016;12(1):e1005315. doi:10.1371/journal.ppat.1005315.
   PubMed Web of Science ®Google Scholar
• Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast A-S, Schoen MK, Rolland M, Suscovich TJ, et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med. 2014;6(228):228ra238. doi:10.1126/scitranslmed.3007736.
   Web of Science ®Google Scholar
• Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, et al. Comparison of antibody responses induced by RV144, VAX003, and VAX004 vaccination regimens. AIDS Res Hum Retrovir. 2017;33(5):410–23. doi:10.1089/AID.2016.0204.
   PubMed Web of Science ®Google Scholar
• Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang Z-Y, Seaton KE, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014;6(228):228ra239. doi:10.1126/scitranslmed.3007730.
   Web of Science ®Google Scholar
• Fischinger S, Shin S, Boudreau CM, Ackerman M, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kim JH, Robb ML, Michael NL, et al. Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight. 2020;5(12). doi:10.1172/jci.insight.135057.
   Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–88. doi:10.1038/s41586-020-2607-z.
   PubMed Web of Science ®Google Scholar
• Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, Borducchi EN, Smith KM, Nkolola JP, Liu J, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–24. doi:10.1126/science.aab3886.
   PubMed Web of Science ®Google Scholar
• Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110(5):1893–98. doi:10.1073/pnas.1209591110.
   PubMed Web of Science ®Google Scholar
• Koch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson EV, Escudero-Pérez B, Pillny M, Ly ML, Koundouno FR, Bore JA, et al. Ebola virus disease survivors show more efficient antibody immunity than vaccines despite similar levels of circulating immunoglobulins. Viruses. 2020;12(9):915. doi:10.3390/v12090915.
   PubMed Web of Science ®Google Scholar
• Marzi A, Robertson SJ, Haddock E, Feldmann F, Hanley PW, Scott DP, Strong JE, Kobinger G, Best SM, Feldmann H, et al. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349(6249):739–42. doi:10.1126/science.aab3920.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505–18. doi:10.1016/S0140-6736(16)32621-6.
   PubMed Web of Science ®Google Scholar
• Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT, Beigel JH. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med. 2016;22(12):1439–47. doi:10.1038/nm.4201.
   PubMed Web of Science ®Google Scholar
• Boudreau CM, Yu W-H, Suscovich TJ, Talbot HK, Edwards KM, Alter G. Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. J Clin Invest. 2020;130(2):662–72. doi:10.1172/JCI129520.
   PubMed Web of Science ®Google Scholar
• Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 2017;1:2329–42. doi:10.1182/bloodadvances.2017011411.
   PubMed Web of Science ®Google Scholar
• Chu TH, Patz EF Jr., Ackerman ME. Coming together at the hinges: therapeutic prospects of IgG3. mAbs. 2021;13:1882028. doi:10.1080/19420862.2021.1882028.
   PubMed Web of Science ®Google Scholar
• Saito S, Namisaki H, Hiraishi K, Takahashi N, Iida S. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress. Protein Sci. 2019;28:900–09. doi:10.1002/pro.3598.
   PubMed Web of Science ®Google Scholar
• Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, De Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2:599. doi:10.1038/ncomms1608.
   PubMed Web of Science ®Google Scholar
• de Sousa-Pereira P, Woof JM. IgA: structure, function, and developability. Antibodies (Basel). 2019:8. doi:10.3390/antib8040057.
   PubMedGoogle Scholar
• Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J, Devilliers H, Ghillani P, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577):eabd2223. doi:10.1126/scitranslmed.abd2223.
   PubMed Web of Science ®Google Scholar
• Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, Cipolla M, Hoffmann -H-H, Oliveira TY, Oren DA, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2021;13(577):eabf1555. doi:10.1126/scitranslmed.abf1555.
   PubMed Web of Science ®Google Scholar
• Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast A-S, Boesch AW, Streeck H, Kwon DS, Ackerman ME, et al. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol. 2016;9(6):1584–95. doi:10.1038/mi.2016.12.
   PubMed Web of Science ®Google Scholar
• Maurer MA, Meyer L, Bianchi M, Turner HL, Le NPL, Steck M, Wyrzucki A, Orlowski V, Ward AB, Crispin M, et al. Glycosylation of human IgA directly inhibits influenza A and other sialic-acid-binding viruses. Cell Rep. 2018;23(1):90–99. doi:10.1016/j.celrep.2018.03.027.
   PubMed Web of Science ®Google Scholar
• Strasser R, Stadlmann J, Schähs M, Stiegler G, Quendler H, Mach L, Glössl J, Weterings K, Pabst M, Steinkellner H, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008;6(4):392–402. doi:10.1111/j.1467-7652.2008.00330.x.
   PubMed Web of Science ®Google Scholar
• Termini JM, Martinez-Navio JM, Gao G, Fuchs SP, Desrosiers RC. Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity. Mol Ther Methods Clin Dev. 2021;20:204–17. doi:10.1016/j.omtm.2020.11.001.
   PubMed Web of Science ®Google Scholar
• Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452–57. doi:10.1038/316452a0.
   PubMed Web of Science ®Google Scholar
• Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, Brown R, Goepfert PA, Mestecky J. Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals. Aids. 2005;19(4):381–89. doi:10.1097/01.aids.0000161767.21405.68.
   PubMed Web of Science ®Google Scholar
• Mahan AE, Jennewein MF, Suscovich T, Dionne K, Tedesco J, Chung AW, Streeck H, Pau M, Schuitemaker H, Francis D, et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog. 2016;12(3):e1005456. doi:10.1371/journal.ppat.1005456.
   PubMed Web of Science ®Google Scholar
• Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr SJ, Berger M, Petzold D, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med. 2012;18:1401–06. doi:10.1038/nm.2862.
   PubMed Web of Science ®Google Scholar
• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs. 2010;2:181–89. doi:10.4161/mabs.2.2.11158.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103:4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol. 2011;85:10572–81. doi:10.1128/JVI.05541-11.
   PubMed Web of Science ®Google Scholar
• Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci U S A. 2012;109:6181–86. doi:10.1073/pnas.1203954109.
   PubMed Web of Science ®Google Scholar
• Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J Immunol. 1995;155:1165–74.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Bonvini E, Koenig S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67:8882–90. doi:10.1158/0008-5472.CAN-07-0696.
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre M-L, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PWHI, Bluestone JA, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200(1):16–26. doi:10.1006/cimm.2000.1617.
   PubMed Web of Science ®Google Scholar
• Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, Joyce PF, Szymkowski DE, Desjarlais JR. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol. 2008;45:3926–33. doi:10.1016/j.molimm.2008.06.027.
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJR, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–63. doi:10.1126/science.1248943.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178–84. doi:10.4049/jimmunol.164.8.4178.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166:2571–75. doi:10.4049/jimmunol.166.4.2571.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169:5171–80. doi:10.4049/jimmunol.169.9.5171.
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, Lowman HB. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol. 2009;182:7663–71. doi:10.4049/jimmunol.0804182.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG 1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35:86–94. doi:10.1124/dmd.106.011734.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28:157–59. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem. 2004;279(8):6213–16. doi:10.1074/jbc.C300470200.
   PubMed Web of Science ®Google Scholar
• Atyeo C, Slein MD, Fischinger S, Burke J, Schäfer A, Leist SR, Kuzmina NA, Mire C, Honko A, Johnson R, et al. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight. 2021;6. doi:10.1172/jci.insight.143129.
   Web of Science ®Google Scholar
• Brown JA, Singh G, Acklin JA, Lee S, Duehr JE, Chokola AN, Frere JJ, Hoffman KW, Foster GA, Krysztof D, et al. Dengue virus immunity increases zika virus-induced damage during pregnancy. Immunity. 2019;50(3):751–762 e755. doi:10.1016/j.immuni.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Zimmerman MG, Quicke KM, O’Neal JT, Arora N, Machiah D, Priyamvada L, Kauffman RC, Register E, Adekunle O, Swieboda D, et al. Cross-reactive dengue virus antibodies augment zika virus infection of human placental macrophages. Cell Host Microbe. 2018;24(5):731–742 e736. doi:10.1016/j.chom.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 2010;6(2):e1000790. doi:10.1371/journal.ppat.1000790.
   PubMed Web of Science ®Google Scholar
• Nonaka M, Kimura A. Genomic view of the evolution of the complement system. Immunogenetics. 2006;58:701–13. doi:10.1007/s00251-006-0142-1.
   PubMed Web of Science ®Google Scholar
• Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics. 2011;63:351–62. doi:10.1007/s00251-011-0514-z.
   PubMed Web of Science ®Google Scholar
• Chan YN, Boesch AW, Osei-Owusu NY, Emileh A, Crowley AR, Cocklin SL, Finstad SL, Linde CH, Howell RA, Zentner I, et al. IgG binding characteristics of rhesus macaque FcgammaR. J Immunol. 2016;197:2936–47. doi:10.4049/jimmunol.1502252.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005;310:1510–12. doi:10.1126/science.1118948.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs. 2017;9(5):767–73. doi:10.1080/19420862.2017.1323159.
   PubMed Web of Science ®Google Scholar